Last reviewed · How we verify
NCT06237192
MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients
NA trial testing blinatumomab for B-ALL, venetoclax for T-ALL in Precursor Cell Lymphoblastic Leukemia-Lymphoma in 200 participants. Currently enrolling.
1 September 2026
Quick facts
| Lead sponsor | National Research Center for Hematology, Russia |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 April 2023 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2027 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- blinatumomab for B-ALL, venetoclax for T-ALL — full drug profile →
Conditions studied
- Precursor Cell Lymphoblastic Leukemia-Lymphoma — all drugs for Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Sponsor
National Research Center for Hematology, Russia — full company profile →
Who can join
Adults 18 to 55, any sex, with Precursor Cell Lymphoblastic Leukemia-Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-intensive But Non-interruptive Treatment based on previously study RALL-2016 of Adult Ph-negative Acute Lymphoblastic Leukemia: No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL patients in complete remission (CR) with MRD-positive status after 2nd induction receive consolidation 1-3 with venetoclax (56 days), and B-ALL patients in complete remission (CR) with MRD-positive status after 2nd induction receive 1 consolidation with blinatumomab. After that consolidation bone samples are collected and tested for MRD and patients will continue therapy by protocol without HSCT if MRD-negative (by flow cytometry by aberrant immunophenotype in a centralized lab) status was achieved.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia.
Shahzad M, Amin MK, Badar T. · · 2025 · PMID 40940843 · DOI 10.3390/cancers17172746 -
EHA2024 Hybrid Congress
· 2024
Verify or expand the search:
- PubMed search for NCT06237192
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma
Currently open trials in the same condition.
- NCT06709469 — Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescent · Phase 1 · recruiting
- NCT06765876 — CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial · EARLY_PHASE1 · recruiting
- NCT06387121 — Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL · Phase 2 · recruiting
- NCT05968963 — Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantat · NA · active not recruiting
- NCT05873322 — Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents Wi · recruiting
Other National Research Center for Hematology, Russia trials
Trials by the same sponsor.
- NCT06721598 — An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproli · not yet recruiting
- NCT06705530 — A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphop · Phase 1, PHASE2 · completed
- NCT06188676 — Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunother · Phase 3 · recruiting
- NCT05158608 — Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis · Phase 3 · unknown
- NCT05165719 — Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06237192 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Research Center for Hematology, Russia
- Last refreshed: 1 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06237192.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing